{"filing":{"accession_number":"0001628280-26-038793","cik":"0001088856","ticker":"CORT","company_name":"CORCEPT THERAPEUTICS INC","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"cort-20260521.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1088856/000162828026038793/cort-20260521.htm"},"events":[{"id":8573,"run_id":7525,"accession_number":"0001628280-26-038793","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Corcept Therapeutics held its Annual Meeting of Stockholders on May 21, 2026, with shareholders voting on four proposals: election of eight directors, ratification of Ernst \u0026 Young LLP as auditor, advisory approval of named executive officer compensation, and approval of the Amended 2024 Incentive Award Plan increasing available shares by 8,000,000.","company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","filing_date":"2026-05-28","form":"8-K","submitted_at":null,"items":[{"id":2503,"accession_number":"0001628280-26-038793","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2024 Incentive Award Plan that increases available shares by 8,000,000 and clarifies plan language. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves material modification of an equity incentive plan that affects compensation available to directors and officers. The increase in share pool and plan amendment are material to investors assessing executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T03:06:15.899621+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2504,"accession_number":"0001628280-26-038793","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Corcept's May 21, 2026 Annual Meeting, covering four proposals: election of eight directors, ratification of Ernst \u0026 Young LLP as auditor, advisory approval of named executive officer compensation, and approval of the Amended 2024 Plan. The filing provides detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T03:06:15.899621+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2503,"accession_number":"0001628280-26-038793","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2024 Incentive Award Plan that increases available shares by 8,000,000 and clarifies plan language. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves material modification of an equity incentive plan that affects compensation available to directors and officers. The increase in share pool and plan amendment are material to investors assessing executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T03:06:15.899621+00:00","company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","filing_date":"2026-05-28"},{"id":2504,"accession_number":"0001628280-26-038793","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Corcept's May 21, 2026 Annual Meeting, covering four proposals: election of eight directors, ratification of Ernst \u0026 Young LLP as auditor, advisory approval of named executive officer compensation, and approval of the Amended 2024 Plan. The filing provides detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T03:06:15.899621+00:00","company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","filing_date":"2026-05-28"}]}